Benitec Biopharma Inc. (BNTC): Nasdaq/NYSE listing notice — Benitec Biopharma regains Nasdaq minimum bid price compliance

Benitec Biopharma Inc.

Received Nasdaq notice on Aug 9, 2023, confirming compliance with Bid Price Rule 5550(a)(2).
Compliance achieved after closing price at $1.00/share or higher for 10 consecutive trading days.
Original deficiency notice was received on Sep 6, 2022, for bid price below $1.00 for 30 days.
Nasdaq has closed the matter; no further action required from the company.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Benitec Biopharma Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

August 9, 2023, the Company received written notice from the Listing Qualifications Department of Nasdaq informing the Company that it has regained compliance with the Bid Price Rule based on the closing price of the Company’s common stock having been at $1.00 per share or greater for 10 consecutive trading days and that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: August 10, 2023 /s/ Jerel

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.